Aracari Biosciences

Aracari Biosciences, founded in 2020 and based in San Diego, CA, is a private preclinical-stage company operating at the intersection of oncology and advanced drug delivery models. The company's core innovation is a suite of vascularized tissue chip platforms (VMO™, VMT™, VMB™) that incorporate human blood vessels to create more realistic human tissue and tumor models for drug testing. By offering these as a service to pharmaceutical and biotech partners, Aracari seeks to improve the predictive power of preclinical studies, reduce late-stage drug failures, and speed the development of novel therapeutics. Their technology is particularly relevant for testing anti-angiogenic drugs, oncology therapeutics, and compounds targeting the blood-brain barrier.

Proprietary vascularized microphysiological systems (tissue chips) featuring self-assembled human blood vessels. Platforms include Vascularized Micro-Organ (VMO™), Vascularized Micro-Tumor (VMT™), and Vascularized Micro-Brain (VMB™) for modeling drug delivery, efficacy, toxicity, and blood-brain barrier permeability.

Aracari competes in the organ-on-a-chip and complex 3D cell culture market against players like Emulate, Mimetas, CN Bio, and TissUse. Its key differentiator is the specific focus on integrated, self-assembled human vasculature, a feature not fully replicated by all competitors. It also competes with traditional preclinical CROs and animal testing models.